emerg
data
support
role
antibodi
fcmediat
antivir
activ
vaccin
efficaci
control
replic
broadli
neutral
antibodi
antibodymedi
viru
intern
fcmediat
function
may
act
portal
entri
wherebi
effector
cell
may
trigger
preexist
antibodi
prevent
acquisit
understand
capac
antibodi
mediat
intern
virion
primari
monocyt
critic
understand
full
antivir
potenc
antibodi
isotypessubclass
differ
function
profil
consequ
antivir
activ
instanc
vaccin
trial
achiev
partial
efficaci
env
iga
correl
increas
risk
infect
ie
decreas
vaccin
efficaci
wherea
correl
decreas
risk
infect
ie
increas
vaccin
efficaci
thu
understand
differ
function
attribut
specif
iga
antibodi
help
defin
mechan
immun
protect
util
vitro
flow
cytometr
method
util
primari
monocyt
phagocyt
infecti
virion
target
determin
capac
env
iga
antibodi
mediat
infecti
virion
intern
importantli
broadli
neutral
antibodi
ie
igg
nonbroadli
neutral
antibodi
ie
mab
mucos
igg
mediat
intern
virion
furthermor
found
env
multipl
specif
ie
mediat
increas
infecti
virion
intern
env
specif
env
iga
mediat
decreas
infecti
virion
intern
compar
data
plo
pathogen
antibodi
critic
part
immun
respons
pathogen
exert
protect
function
via
multitud
mechan
involv
fv
fc
domain
antibodi
includ
direct
pathogen
captur
neutral
well
mechan
antibodydepend
cell
cytotox
adcc
antibodydepend
phagocytosi
adcp
engag
innat
immun
cell
effector
clear
infect
host
cell
immun
complex
opson
viru
apart
direct
sequestr
destruct
pathogen
engag
innat
immun
cell
also
influenc
downstream
adapt
immun
respons
stimul
secret
inflammatori
mediat
recent
data
highlight
protect
infect
well
inhibit
replic
establish
infect
may
mediat
direct
neutral
also
fcmediat
antibodi
effector
function
immun
correl
analysi
partial
efficaci
vaccin
trial
identifi
igg
antibodi
correl
decreas
risk
infect
antibodi
broadli
neutral
capabl
multipl
antivir
function
adcc
virion
captur
neutral
notabl
vaccin
regimen
elicit
antibodi
nonbroadli
neutral
exhibit
coordin
fcmediat
effector
respons
fcr
polymorph
also
influenc
vaccin
efficaci
vaccin
efficaci
trial
show
efficaci
either
lack
coordin
fcmediat
effector
respons
lack
evid
strong
fcmediat
antibodi
function
rhesu
macaqu
challeng
model
nonbroadli
neutral
antibodi
function
includ
phagocytosi
correl
vaccin
protect
thu
result
human
nonhuman
primat
vaccin
clinic
trial
rais
hypothesi
fcmediat
antibodi
effector
function
achiev
potenti
protect
antivir
immun
respons
induc
prevent
vaccin
fc
effector
function
import
vaccin
also
cure
passiv
immunotherapi
strategi
revolv
around
deliveri
broadli
neutral
antibodi
bnab
although
broadli
neutral
antibodi
bnab
defin
base
abil
neutral
broad
rang
virus
recent
passiv
immun
trial
show
protect
activ
sole
due
neutral
also
part
due
fcmediat
function
nonhuman
primat
nhp
passiv
immun
studi
high
low
dose
vagin
challeng
rhesu
macaqu
protect
decreas
administ
passiv
antibodi
incap
bind
fc
receptor
similarli
murin
passiv
immun
studi
antibodi
enhanc
abil
bind
activ
fc
receptor
gave
greater
protect
epitopematch
counterpart
find
also
demonstr
viral
pathogen
instanc
broadli
neutral
antibodi
influenza
demonstr
depend
fcfcr
interact
mediat
protect
vivo
nonfucosyl
glycovari
antirsv
igg
palivizumab
also
show
significantli
improv
protect
vivo
studi
focu
antibodi
fc
effector
function
phagocytosi
antibodydepend
phagocytosi
best
known
essenti
role
defens
extracellular
bacteri
fungal
pathogen
also
shown
play
import
role
clear
viral
intracellular
infect
includ
influenza
west
nile
viru
adenoviru
sar
coronaviru
sarscov
footandmouth
diseas
viru
fmdv
notabl
sarscov
fmdv
protect
mediat
neutral
antibodydepend
phagocytosi
despit
presenc
neutral
antibodi
fmdv
antibodi
mediat
antibodydepend
intern
show
greater
breadth
activ
heterolog
strain
compar
neutral
antibodi
field
antibodymedi
phagocytosi
correl
reduc
risk
infect
nhp
vaccin
studi
human
associ
respons
correl
decreas
risk
infect
sinc
phagocyt
present
mucos
surfac
site
transmiss
hiv
antibodydepend
phagocytosi
may
play
role
prevent
mucos
transmiss
role
phagocytosi
influenc
diseas
progress
also
demonstr
polymorph
one
major
receptor
respons
iggmedi
adcp
correl
progress
suscept
addit
impair
phagocytosi
one
hallmark
chronic
infect
differ
antibodi
isotyp
subclass
appear
vari
abil
protect
infect
one
key
question
vaccin
design
antibodi
isotyp
subclass
induc
vaccin
maxim
protect
instanc
vaccin
trial
serum
env
iga
correl
increas
risk
infect
potenti
due
monomer
circul
iga
block
igg
mediat
adcc
natur
killer
nk
cell
also
antibodi
correl
decreas
risk
infect
antibodi
associ
fc
mediat
antivir
activ
adcc
phagocyt
activ
though
unclear
whether
profil
directli
contribut
antivir
activ
differ
also
found
variou
effector
function
includ
neutral
viru
captur
transcytosi
inhibit
differ
antibodi
physiolog
local
may
also
play
infect
occur
primarili
via
mucos
rout
iga
present
higher
concentr
igg
thu
mechan
behind
antibodi
isotypessubclass
affect
protect
efficaci
remain
unclear
requir
studi
given
fcr
vari
affin
immunoglobulin
subclass
fc
domain
fcfcr
affin
found
correl
phagocyt
activ
phagocyt
activ
like
vari
depend
fcr
antibodi
subclass
involv
detail
evalu
fcmediat
antibodi
function
differ
specif
form
vaccineinduc
antibodi
passiv
administ
broadli
neutral
antibodi
improv
strategi
aim
prevent
andor
control
infect
vivo
although
potenti
protect
antibodymedi
phagocytosi
infect
discuss
previous
sever
studi
impact
antibodi
structur
includ
paratop
isotypesubclass
phagocytosi
potenc
directli
assess
studi
use
model
system
compris
antigen
conjug
bead
monocyt
cell
line
instead
infecti
virion
primari
human
phagocyt
studi
assess
role
antibodi
mediat
phagocytosi
infecti
virion
primari
monocyt
found
antibodymedi
intern
virion
requir
neutral
function
antibodi
paratop
isotypesubclass
find
rais
hypothesi
antibodi
isotypesubclass
profil
may
differ
protect
efficaci
due
differ
potenc
antibodymedi
phagocytosi
implic
current
vaccin
passiv
immun
strategi
human
peripher
blood
mononuclear
cell
neg
individu
vagin
weck
posit
women
collect
irb
approv
duke
medicin
institut
review
board
clinic
investig
subject
consent
follow
cfr
written
inform
consent
obtain
particip
minor
recruit
studi
human
peripher
blood
mononuclear
cell
neg
individu
collect
mucos
weck
collect
seroposit
individu
addit
monocyt
purifi
blood
pack
purchas
blood
bank
red
cross
blood
deriv
monocyt
isol
peripher
blood
mononuclear
cell
pbmc
neg
healthi
donor
use
human
monocyt
isol
kit
ii
automac
magnet
neg
select
bead
miltenyi
biotech
via
elutri
monocyt
cell
purchas
atcc
grown
supplement
fb
penicillinstreptomycin
fluoresc
label
bal
tomato
tomato
mcherri
gener
describ
briefli
label
viru
gener
cotransfect
cell
provir
plasmid
plasmid
encod
gag
protein
fuse
ctermin
fluoresc
molecul
viru
stock
purifi
cell
supernat
bal
provir
plasmid
compris
code
sequenc
clone
backbon
provir
plasmid
compris
code
sequenc
clone
backbon
biotinyl
envelop
antigen
conjug
neutravidin
fluoresc
bead
invitrogen
describ
briefli
bsapbswash
bead
incub
biotinyl
antigen
overnight
rotat
unbound
antigen
remov
wash
twice
ml
bsapb
epitopematch
subclassspecif
recombin
monoclon
antibodi
target
multipl
region
envelop
bind
site
immunodomin
region
bind
site
core
influenza
hemagglutinin
ha
gener
gene
express
construct
briefli
immunoglobulin
variabl
heavychain
v
h
lightchain
v
l
gene
segment
de
novo
synthes
genscript
clone
vector
contain
full
length
constant
region
gene
light
chain
constant
region
gene
transient
transfect
cell
use
polyethyleneimin
pei
polysci
inc
supernat
harvest
day
incub
co
concentr
affin
purifi
protein
g
peptid
chromatographi
per
manufactur
instruct
pierc
thermofish
scientif
antibodi
puriti
evalu
sdspage
coomassi
blue
stain
heavi
light
chain
band
appropri
size
two
form
recombin
mab
produc
wildtyp
antibodi
design
iggsek
term
antibodi
optim
human
bind
via
introduct
alanin
mutat
fc
region
posit
wildtyp
antibodi
produc
base
heavi
chain
constant
region
code
sequenc
antibodymedi
phagocytosi
assay
perform
describ
follow
modif
briefli
bead
equival
suppli
suspens
dilut
fluoresc
label
bal
contain
ng
ng
mix
final
concentr
monoclon
antibodi
well
round
bottom
plate
experi
posit
neg
control
perform
stock
concentr
viru
incub
hour
primari
monocyt
cell
ad
well
final
volum
spinocul
g
hour
block
perform
order
reduc
background
level
viru
intern
due
interact
block
achiev
pretreat
cell
cellsml
antihuman
antibodi
clone
biolegend
minut
ad
antibodybeadsviru
mixtur
nevertheless
similar
pattern
antibodydepend
signal
observ
block
omit
experiment
setup
follow
spinocul
antigensvirus
cell
incub
hour
phagocytosisvirion
intern
incub
supernat
remov
cell
wash
pb
cell
fix
paraformaldehyd
calcul
phagocytosi
score
bead
base
phagocytosi
assay
virion
intern
assay
cutoff
first
assign
base
th
percentil
noantibodi
control
sampl
cell
cutoff
multipli
mean
fluoresc
intens
mfi
normal
correspond
result
noantibodi
control
give
final
score
background
level
phagocytosi
determin
base
mean
standard
deviat
sd
nonhivspecif
antibodi
confirm
robust
calcul
score
altern
method
calcul
also
use
includ
divid
sampl
mfi
noantibodi
control
mfi
without
assign
posit
cutoff
well
subtract
sampl
mfi
noantibodi
control
mfi
altern
method
calcul
gave
similar
result
robust
assay
confirm
multipl
scientist
obtain
similar
result
control
antibodi
also
replic
key
phagocytosi
experi
obtain
rang
phagocytosi
score
give
assay
dynam
rang
relev
fold
differ
phagocytosi
score
calcul
divis
antibodydepend
intern
compon
phagocytosi
score
baselinesubtract
use
formula
phagocytosi
score
phagocytosi
score
calcul
use
condit
antibodydepend
compon
phenotyp
fcr
monocyt
cell
incub
aquady
surfac
stain
titrat
amount
fluor
bd
bioscienc
invitrogen
follow
wash
cell
fix
formaldehyd
flow
data
acquir
lsrii
flow
cytomet
bd
immunocytometri
system
data
analys
use
flowjo
softwar
treestar
receptor
block
antibodi
mous
antihuman
monoclon
antibodi
abcam
preincub
primari
monocyt
least
hour
prior
mix
opson
bead
percentag
block
calcul
base
divis
antibodydepend
intern
compon
phagocytosi
score
baselinesubtract
use
formula
phagocytosi
score
phagocytosi
score
without
bind
kinet
measur
octet
instrument
control
data
acquisit
softwar
two
set
biosensor
regener
glycin
buffer
ph
ge
healthcar
scienc
total
second
respect
separ
load
set
antihuman
igg
fc
captur
ahc
biosensor
termin
load
upon
reach
shift
antibodi
match
set
load
biosensor
dip
simultan
pb
buffer
second
equilibr
biosensor
follow
second
pb
establish
baselin
follow
second
sampl
analyt
gdneg
purifi
high
perform
liquid
chromatographi
hplc
obtain
monom
associ
final
second
baselin
pb
dissoci
associ
dissoci
measur
rang
antigen
gdneg
concentr
increment
well
blank
pb
temperatur
agit
speed
distanc
tip
acquisit
rate
instrument
set
rpm
hz
averag
respect
data
fit
langmuir
fit
model
perform
data
analysi
softwar
report
associ
dissoci
valu
calcul
curv
fit
subtract
neg
control
respect
exclud
nonspecif
bind
interact
similar
result
obtain
associ
dissoci
without
neg
control
subtract
imagestream
cytometri
analysi
virion
intern
phagocytosi
assay
run
describ
except
larger
pool
cell
primari
monocyt
final
concentr
million
cellsml
use
fixat
cell
wash
resuspend
bsapb
antibodymedi
virion
intern
monocyt
analys
use
imagestream
x
mark
ii
imag
flow
cytomet
emd
millipor
fluoresc
viru
imag
collect
channel
nm
magnif
focus
singl
cell
base
gate
gradient
rm
area
aspect
ratio
brightfield
imag
chosen
analysi
ivca
method
util
protein
g
column
base
captur
igvirion
immun
complex
two
readout
quantifi
total
viru
particl
rtpcr
infecti
virion
tzmbl
infect
assay
previous
describ
briefli
igg
mix
stock
final
concentr
volum
form
abvirion
immun
complex
ic
pass
protein
g
column
infect
flowthrough
measur
tzmbl
infect
assay
total
viru
particl
flowthrough
columncaptur
fraction
measur
gag
realtim
rtpcr
percentag
captur
infecti
virion
ivirion
total
virion
captur
rvirion
calcul
independ
differ
denomin
follow
ivirion
infect
viru
noab
infect
x
rvirion
captur
viral
rna
copi
captur
viral
rna
flowthrough
viral
rna
x
purifi
genit
mucos
igg
women
prepar
describ
bind
mucos
antibodi
env
protein
measur
custom
bind
antibodi
multiplex
assay
describ
env
protein
use
includ
clade
b
bal
consensu
con
loop
clade
b
casea
resurfac
core
rsc
protein
reveal
mutant
abolish
antibodi
bind
rsc
protein
kind
gift
dr
john
mascola
total
igg
iga
ab
measur
calcul
specif
activ
perform
use
bioplex
pro
human
isotyp
panel
biorad
accord
manufactur
instruct
statist
analys
perform
sa
sa
institut
cari
nc
differ
antibodymedi
virion
intern
among
isotyp
subclass
determin
sign
test
linear
mix
effect
model
proc
mix
control
fals
discoveri
rate
fdr
perform
use
benjamini
hochberg
method
statist
comparison
applic
result
separ
assay
use
primari
monocyt
donor
averag
treat
singl
data
point
box
plot
dot
plot
graph
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
antibodymedi
phagocytosi
infect
cell
antibodymedi
intern
virion
exert
import
antivir
activ
number
pathogen
much
unknown
antibodyfc
mediat
phagocytosi
sinc
infect
occur
predominantli
via
mucos
rout
sinc
iga
play
import
role
mucos
immun
examin
abil
specif
iga
mediat
phagocytosi
env
bead
howev
use
monocyt
cell
line
phagocytosi
assay
develop
observ
low
level
phagocyt
activ
shown
low
level
phagocyt
activ
mediat
specif
broadli
neutral
bind
site
antibodi
monomer
backbon
fig
sinc
antibodydepend
phagocytosi
depend
engag
fc
receptor
hypothes
cell
might
express
differ
fc
receptor
profil
compar
primari
monocyt
aberr
express
iga
fc
receptor
cell
might
caus
lack
igamedi
phagocyt
activ
inde
phenotyp
fc
receptor
fcr
express
monocyt
cell
well
freshli
isol
blood
deriv
monocyt
neg
healthi
donor
observ
monocyt
exhibit
differ
fcr
profil
fig
iga
receptor
lower
express
found
cell
compar
primari
monocyt
median
mfi
respect
primari
monocyt
express
similar
high
level
median
mfi
respect
contrast
cell
express
higher
level
primari
monocyt
median
mfi
respect
cell
primari
monocyt
express
low
level
igg
receptor
median
mfi
respect
similar
previou
report
classic
monocyt
result
suggest
use
infecti
virion
primari
phagocyt
instead
envelopeconjug
bead
may
better
mimic
vivo
condit
thu
provid
precis
inform
antibodymedi
virion
intern
expect
igamedi
phagocytosi
activ
much
higher
primari
monocyt
phagocyt
assay
instead
cell
specif
antibodi
demonstr
higher
envelop
conjug
bead
uptak
primari
monocyt
median
phagocytosi
score
compar
cell
median
phagocytosi
score
fig
like
due
lower
express
cell
fig
expect
antibodi
mediat
phagocytosi
envcoat
bead
fig
thu
broadli
neutral
antibodi
specif
iga
isotyp
capabl
mediat
phagocytosi
order
verifi
specif
igamedi
phagocytosi
achiev
via
mechan
block
preincub
monocyt
least
hr
antihuman
prior
initi
phagocytosi
block
abrog
specif
igamedi
phagocytosi
monocyt
bead
dosedepend
respons
observ
block
phagocytosi
mab
respect
fig
bead
size
reduc
size
closer
hiv
virion
block
phagocytosi
observ
mab
fig
thu
igamedi
phagocytosi
primari
monocyt
larg
mediat
immun
complex
ad
cell
uptak
immun
complex
analys
flow
cytometri
repres
histogram
bead
uptak
cell
bnab
neg
control
antiinfluenza
mab
phagocytosi
activ
shown
red
trace
repres
antibodymedi
intern
bead
black
trace
repres
background
intern
bead
absenc
antibodi
grey
solid
area
neg
control
without
inclus
bead
b
cell
primari
monocyt
phenotyp
express
fluoresc
antibodi
stain
flow
cytometri
compens
mfi
valu
report
n
independ
experi
cell
n
independ
experi
primari
monocyt
repres
differ
primari
monocyt
donor
cd
phagocytosi
bead
immun
complex
primari
monocyt
shown
repres
histogram
bead
uptak
bnab
antiinfluenza
mab
phagocytosi
activ
c
bead
phagocytosi
quantifi
use
phagocytosi
score
see
method
dash
line
indic
background
phagocytosi
level
measur
mean
sd
relev
neg
control
result
independ
experi
shown
ef
identifi
whether
block
reduc
igamedi
phagocytosi
primari
monocyt
incub
variou
concentr
antibodi
least
hour
addit
immun
complex
made
fluoresc
bead
repres
histogram
bead
uptak
monocyt
presenc
diga
shown
e
block
antibodymedi
phagocytosi
quantifi
take
differ
phagocytosi
score
experi
conduct
presenc
f
result
independ
experi
shown
watkin
et
al
report
provid
better
protect
shiv
mucos
challeng
model
compar
protect
like
due
recognit
infecti
viru
particl
subsequ
sholukh
et
al
present
confer
protect
mucos
challeng
model
order
determin
abil
differ
isotyp
subclass
specif
antibodi
mediat
phagocytosi
express
antibodi
fc
express
construct
examin
capac
mediat
phagocytosi
hiv
envconjug
bead
three
form
mab
mediat
similar
level
phagocytosi
fluoresc
bead
primari
monocyt
fig
antibodydepend
intern
process
vari
depend
target
properti
given
differ
size
rigid
antigen
densiti
virion
envconjug
bead
hypothes
differ
phagocyt
potenc
igg
iga
might
appar
use
virion
date
abil
specif
antibodi
mediat
intern
infecti
virion
character
thu
investig
effector
function
develop
flow
cytometr
assay
capabl
demonstr
direct
intern
infecti
virion
allow
visual
intern
virion
label
fluoresc
protein
mcherri
tomato
cell
primari
monocyt
capabl
intern
virion
antibodyspecif
manner
fig
intern
evid
despit
treatment
uptak
immun
complex
primari
monocyt
analys
flow
cytometri
box
plot
repres
rang
phagocytosi
score
boxandwhisk
plot
indic
th
th
percentil
box
minimum
maximum
score
whisker
horizont
black
dash
line
indic
limit
detect
calcul
use
mean
sd
neg
control
correspond
assay
c
differ
phagocytosi
score
among
immunoglobulin
isotyp
compar
pairwis
use
sign
test
cell
trypsin
minut
phagocytosi
incub
lyse
surfacebound
unintern
viru
fig
three
form
mab
mediat
uptak
virion
contrast
previou
result
envconjug
bead
use
infecti
virion
target
antigen
show
higher
phagocytosi
potenc
iga
shown
higher
phagocytosi
score
median
phagocytosi
score
median
phagocytosi
score
fdrp
higher
phagocytosi
score
median
phagocytosi
score
fdrp
fig
show
nonsignific
trend
toward
higher
phagocytosi
potenc
fdrp
thu
potent
iga
mediat
virion
intern
determin
impact
igg
subclass
capac
mediat
antibodydepend
virion
intern
broadli
neutral
antibodi
gener
differ
fc
backbon
recombin
wildtyp
sek
wildtyp
result
antibodi
compar
potenc
intern
bead
fig
bal
tomato
virion
fig
tomato
virion
fig
show
nonsignific
trend
fdrp
toward
higher
phagocytosi
bead
median
phagocytosi
score
compar
median
fig
show
significantli
higher
phagocytosi
bal
tomato
virion
median
phagocytosi
score
higher
phagocytosi
score
median
fdrp
fig
pattern
observ
intern
tomato
virion
show
significantli
higher
phagocytosi
tomato
virion
median
phagocytosi
score
higher
phagocytosi
score
median
fdrp
fig
thu
potent
bead
virion
intern
fig
determin
whether
varianc
virion
intern
differ
antibodi
isotyp
subclass
caus
abil
bind
envelop
test
bind
protein
biolay
interferometri
fig
contrast
result
observ
virion
intern
observ
k
valu
mean
k
x
mean
k
x
similar
less
twofold
differ
fig
thu
mediat
increas
bind
env
compar
similar
result
obtain
without
subtract
neg
control
nonspecif
bind
respect
sinc
nonspecif
bind
level
antigen
low
result
indic
virion
intern
assay
distinguish
differ
antibodi
isotyp
subclass
mediat
phagocytosi
distinct
envelop
bind
confirm
igamedi
intern
infecti
virion
primari
monocyt
examin
virion
intern
imagestream
cytometri
techniqu
combin
flow
cytometri
fluoresc
microscopi
phagocytosi
assay
set
similar
previou
experi
except
fix
cell
visual
imagestream
antiinfluenza
mab
subclass
backbon
also
test
neg
control
boxandwhisk
plot
indic
th
th
percentil
box
minimum
maximum
score
whisker
horizont
black
dash
line
indic
limit
detect
calcul
use
mean
sd
neg
control
correspond
assay
differ
phagocytosi
score
compar
use
sign
test
eh
examin
differ
phagocytosi
due
differ
bind
env
antibodi
bind
env
protein
test
use
biolay
interferometri
antibodi
load
human
igg
captur
sensor
bind
gdneg
monom
protein
solut
test
e
specif
bind
curv
cytomet
obtain
cell
imag
per
condit
observ
intern
viru
within
monocyt
seen
distinct
intracellular
fluoresc
puncta
fig
consist
result
obtain
flow
cytometri
show
greater
virion
intern
higher
mean
intens
viru
fluoresc
channel
x
x
x
mfi
respect
fig
valu
antibodi
remain
neg
control
examin
whether
differ
due
surfac
bind
virion
calcul
intens
fluoresc
within
intern
portion
cell
defin
area
remain
erod
pixel
perimet
brightfield
mask
fig
eros
pixel
cell
imag
identifi
intern
area
cell
part
standard
data
analysi
softwar
intern
wizard
imagestream
instrument
sinc
acquir
cell
gate
imag
focu
analyz
cell
fall
within
particular
depth
rang
acquir
imag
repres
crosssect
cell
consist
membran
thick
addit
confirm
techniqu
show
surfacebind
fluoresc
probe
less
fluoresc
exclud
eros
compar
intern
probe
fig
eros
fluoresc
lost
condit
sinc
intens
sum
fluoresc
observ
within
measur
area
decreas
howev
pattern
observ
antibodi
isotyp
subclass
remain
unchang
highest
mean
viru
fluoresc
intens
x
mfi
follow
x
mfi
x
mfi
remain
higher
neg
control
fig
furthermor
percentag
fluoresc
lost
imag
erod
consist
across
antibodi
isotypessubclass
indic
averag
depth
intern
similar
fig
fig
thu
imagestream
analysi
confirm
antibodymedi
intern
viru
particl
addit
quantit
measur
virion
phagocytosi
number
viral
foci
per
cell
count
use
spot
wizard
defin
stringenc
criteria
mask
use
spot
count
imagestream
idea
spot
wizard
algorithm
train
use
two
group
least
focus
singl
cell
manual
classifiedon
low
spot
number
one
high
spot
number
imag
vari
spot
size
shape
intens
background
use
categori
yield
mask
compris
peak
area
defin
spottobackground
ratio
bright
mask
virion
fluoresc
channel
fig
yield
differ
distribut
spot
fig
highest
mean
spot
count
follow
mean
spot
count
follow
mean
spot
count
fig
antibodi
condit
show
higher
spot
count
neg
control
thu
antibodi
isotypessubclass
display
differ
number
viral
foci
per
cell
addit
differ
total
virion
intern
order
identifi
whether
observ
phenomenon
enhanc
phagocytosi
potenc
applic
epitop
bind
site
epitop
gener
epitopematch
antibodi
multipl
epitop
specif
includ
princip
immunodomin
domain
pid
conform
epitop
loop
bind
site
core
conform
epitop
addit
two
bind
light
blue
dark
blue
line
respect
shown
along
langmuir
model
fit
curv
red
line
f
dissoci
constant
k
associ
rate
k
dissoci
rate
k
shown
independ
experi
g
respect
median
valu
also
shown
h
antibodi
form
produc
epitopea
wild
type
sek
adccoptim
form
test
antibodi
phagocytosi
tomato
virion
differ
found
two
form
result
aggreg
antibodi
posit
phagocytosi
backbon
show
higher
phagocytosi
score
backbon
fig
specif
broadli
neutral
antibodi
site
corespecif
nonbroadli
neutral
antibodi
isol
vaccine
pidspecif
show
enhanc
intern
infecti
tomato
virion
median
phagocytosi
score
compar
counterpart
phagocytosi
score
overal
higher
phagocytosi
score
compar
mab
target
epitop
present
virion
epitop
epitop
neither
intern
virion
aggreg
paratop
posit
virion
intern
allow
statist
comparison
subclass
tomato
virion
intern
use
linear
mix
effect
model
show
significantli
higher
phagocytosi
potenc
across
multipl
epitop
p
fig
extend
find
monoclon
antibodi
human
clinic
sampl
relev
mucos
protect
next
test
whether
specif
mucos
igg
femal
genit
tract
could
mediat
virion
intern
previous
report
capac
mucos
igg
vagin
weck
bind
infecti
virion
ie
viru
captur
select
clinic
sampl
evid
virion
recognit
test
intern
phagocyt
thu
isol
igg
vagin
weck
women
test
infecti
virion
captur
bind
differ
part
envelop
includ
loop
bind
site
mucos
iga
test
due
low
yield
specif
iga
sampl
confirm
previou
report
sampl
total
igg
concentr
rang
show
infecti
noninfecti
viru
captur
four
sampl
high
level
antibodi
fig
two
four
particip
loop
bind
two
show
bind
specif
repres
differenti
bind
resurfac
core
protein
compar
mutant
decreas
bind
specif
purifi
igg
four
particip
captur
total
bal
viru
particl
purifi
igg
specif
activ
bal
shown
sampl
fibackground
classifi
neg
classif
like
bind
antibodi
indic
ratio
bind
mfi
mutant
classif
antibodi
indic
differenti
ratio
bind
mfi
core
core
b
abil
mucos
purifi
igg
sampl
mediat
uptak
bal
tomato
cell
analys
flow
cytometri
repres
flow
cytometri
diagram
virion
intern
mediat
mucos
igg
isol
vagin
weck
woman
shown
alongsid
repres
diagram
neg
control
rsvspecif
palivizumab
c
abil
mucos
igg
chronic
infect
women
mediat
viru
captur
virion
intern
quantifi
blue
circl
repres
phagocytosi
score
bal
tomato
virion
cell
n
independ
experi
green
squar
repres
viru
captur
percentag
measur
rtqpcr
n
independ
experi
four
particip
evalu
abil
mediat
virion
intern
inde
mucos
igg
mediat
bal
virion
intern
monocyt
median
phagocytosi
score
fig
thu
human
mucos
igg
individu
capabl
mediat
virion
captur
iggmedi
intern
infecti
demonstr
proof
concept
easili
elicit
antibodi
mediat
potenti
antivir
effector
function
portal
entri
substanti
evid
suggest
role
fcreceptor
mediat
antibodi
function
protect
infect
evalu
fcmediat
virion
intern
primari
monocyt
demonstr
envelop
specif
igg
iga
complex
infecti
virion
lead
phagocytosi
primari
monocyt
potenc
virion
intern
modul
antibodi
fc
potent
follow
iga
furthermor
found
infect
elicit
mucos
igg
recogn
infecti
virion
provid
proof
concept
type
antibodi
easili
elicit
vaccin
provid
partial
block
acquisit
mucos
surfac
studi
need
evalu
potenti
protect
andor
detriment
role
fcmediat
antibodi
function
mucos
site
given
import
antibodi
isotypesubclass
profil
vaccin
efficaci
protect
mucos
challeng
model
sought
determin
differ
effector
function
among
isotypessubclass
identifi
substanti
differ
iga
mediat
virion
intern
use
flow
cytometri
imagestream
cytometri
demonstr
enhanc
virion
intern
compar
reduc
virion
intern
compar
previou
report
improv
protect
function
determin
antibodi
specif
region
envelop
glycoprotein
includ
examin
antibodymedi
phagocytosi
later
work
group
also
demonstr
protect
capac
combin
work
differ
prior
studi
examin
differ
epitop
specif
ie
vs
monomer
vs
dimer
form
iga
differ
type
antivir
function
phagocytosi
vs
virion
captur
transcytosi
work
need
understand
structur
iga
ie
longer
hing
region
benefici
epitop
specif
antivir
function
depend
occlud
expos
target
site
present
pathogen
gener
addit
monoclon
antibodi
test
broader
panel
epitop
specif
determin
whether
effect
observ
specif
particular
epitop
potent
epitop
specif
mediat
virion
intern
indic
observ
effect
epitopedepend
identif
enhanc
mediat
phagocyt
function
support
find
viru
control
vaccine
antibodi
respons
associ
function
antibodi
profil
howev
unlik
chung
et
al
conclud
may
surrog
function
respons
data
present
addit
potenti
role
direct
effector
function
via
enhanc
antibodymedi
phagocytosi
activ
rais
hypothesi
correl
env
reduc
risk
may
part
due
improv
fc
mediat
antivir
function
found
differ
virion
intern
activ
among
antibodi
isotyp
subclass
associ
env
antigen
bind
indic
observ
differ
virion
intern
simpli
due
differ
affin
target
mechan
behind
differ
among
antibodi
subclassesisotyp
mediat
virion
intern
remain
determin
potenti
mechan
divid
effect
paratop
bind
effect
fc
receptor
engag
antibodi
fc
region
regard
paratop
bind
antibodi
isotypessubclass
differ
hing
length
flexibl
angl
fab
arm
differ
may
result
avid
effect
lead
increas
virion
engag
intern
especi
light
rel
number
env
spike
virion
surfac
exampl
potent
neutral
activ
attribut
longer
flexibl
hing
region
exampl
includ
studi
show
dimer
better
mediat
viru
captur
compar
dimer
although
monomer
iga
equal
capabl
mediat
virion
aggreg
regard
differ
fc
receptor
engag
igg
iga
engag
differ
fc
receptor
known
differ
signal
contribut
intern
compar
known
show
stronger
bind
sever
fc
receptor
may
result
observ
enhanc
phagocyt
activ
understand
contribut
fc
receptor
notabl
observ
differ
virion
intern
observ
antibodi
fig
given
aaa
mutat
design
optim
bind
unlik
differ
phagocyt
potenc
contribut
bind
consist
known
low
express
classic
monocyt
well
previou
studi
show
intern
igg
primarili
mediat
interact
primari
monocyt
cell
given
aaa
mutat
enhanc
adcc
find
aaa
mutat
enhanc
phagocytosi
provid
exampl
demonstr
interact
enhanc
one
fcmediat
function
necessarili
also
enhanc
fcmediat
function
studi
relationship
fcr
signal
antibodydepend
intern
need
understand
differ
effector
function
antibodi
isotyp
subclass
sinc
monocytesmacrophag
neutrophil
predomin
fc
receptor
bear
cell
cervicovagin
mucosa
person
commun
dr
r
astronomo
mj
mcelrath
focus
evalu
antivir
potenti
specif
antibodi
primari
monocyt
futur
studi
need
test
mucos
vagin
macrophag
neutrophil
express
ii
iii
understand
potenti
engag
mucos
effector
cell
vaccineelicit
antibodi
respons
iga
domin
antibodi
isotyp
gut
mucosa
demonstr
specif
iga
mab
could
mediat
infecti
virion
intern
primari
monocyt
moreov
mucos
igg
purifi
vagin
weck
infect
women
mediat
phagocytosi
virion
data
provid
proof
concept
certain
specif
antibodi
elicit
vaccin
could
mediat
phagocytosi
viru
particl
mucosa
repres
addit
potenti
antivir
function
virion
intern
mediat
mucos
igg
infect
women
compris
rang
antibodi
epitop
specif
includ
bind
site
interestingli
particip
highest
virion
intern
score
also
highest
bind
score
among
particip
evalu
suggest
bind
site
may
import
target
virion
intern
mucos
surfac
larger
studi
requir
examin
relationship
antibodi
epitop
specif
virion
intern
infect
cell
virion
particl
two
biolog
target
antibodymedi
intern
role
process
infect
unclear
advanc
need
character
inform
strategi
prevent
cure
one
potenti
method
separ
intern
process
util
differ
target
size
associ
differ
mechan
intern
smaller
particl
taken
endocytosi
depend
clathrin
cbl
activ
ubiquitinyl
proteasom
function
larger
particl
taken
phagocytosi
depend
actin
well
activ
src
syk
found
similar
dichotomi
smaller
larger
particl
smaller
particl
includ
bead
nm
bead
virion
higher
phagocytosi
score
primari
monocyt
compar
cell
larger
particl
bead
higher
phagocytosi
score
cell
compar
primari
monocyt
fig
differ
phenotyp
may
point
toward
differ
intern
mechan
virus
compar
bead
rais
hypothesi
virusbas
beadbas
assay
repres
phagocytosi
differ
kind
target
vivo
given
bead
use
intern
target
instead
virion
observ
differ
iga
nonsignific
trend
toward
higher
phagocytosi
potenc
fig
antibodi
isotyp
subclass
may
differ
effect
mediat
cell
virion
phagocytosi
work
compar
mechan
bead
virion
uptak
need
better
understand
correl
risk
identifi
nonhuman
primat
model
use
beadbas
phagocytosi
assay
determin
whether
repres
phagocytosi
infect
cell
viru
particl
identifi
signific
differ
among
antibodi
isotypessubclass
capac
mediat
virion
intern
env
multipl
specif
highest
potenc
follow
moreov
specif
igg
iga
mediat
phagocytosi
infecti
virion
igg
fc
mediat
antivir
activ
activ
vagin
mucosa
data
provid
fundament
insight
fc
mediat
antibodi
effector
function
may
import
protect
acquisit
cure
strategi
cell
incub
bal
tomato
allow
virion
intern
prior
fixat
cell
also
stain
surfac
stain
nuclear
stain
dapi
singl
focus
cell
acquir
use
imagestream
x
mark
ii
emd
millipor
amni
idea
softwar
use
analyz
imag
intens
bal
tomato
dapi
fluoresc
calcul
across
defin
cell
area
pixel
erod
area
defin
entir
brightfield
imag
cell
peripher
area
cell
exclud
calcul
pixel
erod
perimet
brightfield
imag
eros
pixel
thu
fluoresc
peripheri
cell
lost
outer
pixel
erod
surfac
stain
preferenti
lost
compar
nuclear
stain
dapi
pixel
erod
shown
rapid
loss
percent
fluoresc
intens
compar
unerod
imag
indic
eros
pixel
distinguish
intern
surfac
fluoresc
bal
tomato
virion
fluoresc
lost
intermedi
rate
surfac
nuclear
stain
line
assum
endosom
local
intermedi
nucleu
plasma
membran
b
percentag
loss
fluoresc
intens
increas
pixel
eros
graph
bal
tomato
immun
complex
intern
primari
monocyt
similar
fluoresc
intens
loss
occur
eros
increas
indic
depth
intern
immun
complex
similar
across
antibodi
isotypesubclass
experi
primari
monocyt
donor
use
least
replic
donor
except
neg
antibodi
control
use
antibodi
palivizumab
c
compar
effici
cell
primari
monocyt
iggmedi
virion
intern
uptak
bal
tomato
immun
complex
cell
primari
monocyt
donor
least
replic
donor
except
examin
flow
cytometri
n
independ
experi
tif
